3 completed, 1 terminated. 4 Phase 1, 2 Phase 2.
By phase and status
Follow EPZ-5676: new trials by email Literature Review of EPZ-5676 trials Research Report on EPZ-5676
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement Azacitidine, Pinometostat - Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL, Leukemia Cutis | Phase 1 / Phase 2 | Completed | 1 | 2020-03-06 | 2023-10-18 |
Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement Cytarabine, Daunorubicin, Daunorubicin Hydrochloride - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | 6 | 2019-04-10 | 2025-06-18 |
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene EPZ-5676 - Leukemia, Acute Myeloid Leukemia | Phase 1 | Completed | 18 | 2014-05-01 | 2023-06-18 |
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving EPZ-5676 - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Completed | 51 | 2012-09-01 | 2024-03-26 |
Conditions studied
Leukemia, Myeloid, Acute (4) · Leukemia (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Myelodysplastic Syndromes (1) · Myeloproliferative Disorders (1)
Sponsors
Epizyme, Inc. (2) · National Cancer Institute (NCI) (2)
Countries
United States (4) · Canada (1) · Germany (1) · Netherlands (1)
Top investigators
Cynthia Wetmore, MD PhD (1) · David A Rizzieri, MD (1) · Guillermo Garcia-Manero, MD (1) · James S Blachly (1) · Jessica Altman, MD (1) · Jesus Berdeja, MD (1) · Jim A Whitlock, MD (1) · Kamal Menghrajani (1) · Lewis Silverman, MD (1) · Lia Gore, MD (1) · Martin S. Tallman, MD (1) · Maureen O'Brien, MD (1) · Mignon Loh, MD (1)
Results publications
PMID 29724899
NIH funding
UM1CA186691 (1), UM1CA186712 (1)